Literature DB >> 24297176

Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of β-tubulin.

Marie L Antony1, Joomin Lee, Eun-Ryeong Hahm, Su-Hyeong Kim, Adam I Marcus, Vandana Kumari, Xinhua Ji, Zhen Yang, Courtney L Vowell, Peter Wipf, Guy T Uechi, Nathan A Yates, Guillermo Romero, Saumendra N Sarkar, Shivendra V Singh.   

Abstract

Withaferin A (WA), a C5,C6-epoxy steroidal lactone derived from a medicinal plant (Withania somnifera), inhibits growth of human breast cancer cells in vitro and in vivo and prevents mammary cancer development in a transgenic mouse model. However, the mechanisms underlying the anticancer effect of WA are not fully understood. Herein, we report that tubulin is a novel target of WA-mediated growth arrest in human breast cancer cells. The G2 and mitotic arrest resulting from WA exposure in MCF-7, SUM159, and SK-BR-3 cells was associated with a marked decrease in protein levels of β-tubulin. These effects were not observed with the naturally occurring C6,C7-epoxy analogs of WA (withanone and withanolide A). A non-tumorigenic normal mammary epithelial cell line (MCF-10A) was markedly more resistant to mitotic arrest by WA compared with breast cancer cells. Vehicle-treated control cells exhibited a normal bipolar spindle with chromosomes aligned along the metaphase plate. In contrast, WA treatment led to a severe disruption of normal spindle morphology. NMR analyses revealed that the A-ring enone in WA, but not in withanone or withanolide A, was highly reactive with cysteamine and rapidly succumbed to irreversible nucleophilic addition. Mass spectrometry demonstrated direct covalent binding of WA to Cys(303) of β-tubulin in MCF-7 cells. Molecular docking indicated that the WA-binding pocket is located on the surface of β-tubulin and characterized by a hydrophobic floor, a hydrophobic wall, and a charge-balanced hydrophilic entrance. These results provide novel insights into the mechanism of growth arrest by WA in breast cancer cells.

Entities:  

Keywords:  Breast Cancer; Cancer Chemoprevention; Cell Cycle; Natural Products; Tubulin; Withaferin A

Mesh:

Substances:

Year:  2013        PMID: 24297176      PMCID: PMC3894360          DOI: 10.1074/jbc.M113.496844

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.

Authors:  Jie-Guang Chen; Susan Band Horwitz
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

2.  In-gel digestion for mass spectrometric characterization of proteins and proteomes.

Authors:  Andrej Shevchenko; Henrik Tomas; Jan Havlis; Jesper V Olsen; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

3.  Protein structure prediction on the Web: a case study using the Phyre server.

Authors:  Lawrence A Kelley; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 4.  The tubulin code.

Authors:  Kristen J Verhey; Jacek Gaertig
Journal:  Cell Cycle       Date:  2007-06-26       Impact factor: 4.534

5.  Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression.

Authors:  Haruyo Ichikawa; Yasunari Takada; Shishir Shishodia; Bolleddula Jayaprakasam; Muraleedharan G Nair; Bharat B Aggarwal
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

6.  Transition states and energetics of nucleophilic additions of thiols to substituted α,β-unsaturated ketones: substituent effects involve enone stabilization, product branching, and solvation.

Authors:  Elizabeth H Krenske; Russell C Petter; Zhendong Zhu; K N Houk
Journal:  J Org Chem       Date:  2011-05-16       Impact factor: 4.354

Review 7.  Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone.

Authors:  Avani R Vyas; Shivendra V Singh
Journal:  AAPS J       Date:  2013-09-18       Impact factor: 4.009

Review 8.  Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents.

Authors:  R F Luduena; M C Roach
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

9.  Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells.

Authors:  Silvia D Stan; Yan Zeng; Shivendra V Singh
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

10.  Roots of Withania somnifera Inhibit Forestomach and Skin Carcinogenesis in Mice.

Authors:  Bandhuvula Padmavathi; Pramod C Rath; Araga Ramesha Rao; Rana Pratap Singh
Journal:  Evid Based Complement Alternat Med       Date:  2005-02-09       Impact factor: 2.629

View more
  38 in total

Review 1.  Withania somnifera: From prevention to treatment of cancer.

Authors:  Dushani L Palliyaguru; Shivendra V Singh; Thomas W Kensler
Journal:  Mol Nutr Food Res       Date:  2016-01-29       Impact factor: 5.914

2.  A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers.

Authors:  Michael J Bollong; Mika Pietilä; Aaron D Pearson; Tapasree Roy Sarkar; Insha Ahmad; Rama Soundararajan; Costas A Lyssiotis; Sendurai A Mani; Peter G Schultz; Luke L Lairson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-30       Impact factor: 11.205

3.  Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.

Authors:  Suman K Samanta; Anuradha Sehrawat; Su-Hyeong Kim; Eun-Ryeong Hahm; Yongli Shuai; Ruchi Roy; Subrata K Pore; Krishna B Singh; Susan M Christner; Jan H Beumer; Nancy E Davidson; Shivendra V Singh
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 4.  A Comprehensive Review and Perspective on Anticancer Mechanisms of Withaferin A in Breast Cancer.

Authors:  Eun-Ryeong Hahm; Su-Hyeong Kim; Krishna B Singh; Kamayani Singh; Shivendra V Singh
Journal:  Cancer Prev Res (Phila)       Date:  2020-07-29

5.  The Daniel K. Inouye College of Pharmacy Scripts: Poha Berry (Physalis peruviana) with Potential Anti-inflammatory and Cancer Prevention Activities.

Authors:  Leng Chee Chang; Mayuramas Sang-Ngern; John M Pezzuto; Carolyn Ma
Journal:  Hawaii J Med Public Health       Date:  2016-11

6.  Covalent modification of Cys-239 in β-tubulin by small molecules as a strategy to promote tubulin heterodimer degradation.

Authors:  Jianhong Yang; Yong Li; Wei Yan; Weimin Li; Qiang Qiu; Haoyu Ye; Lijuan Chen
Journal:  J Biol Chem       Date:  2019-04-02       Impact factor: 5.157

7.  Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.

Authors:  Eun-Ryeong Hahm; Joomin Lee; Terric Abella; Shivendra V Singh
Journal:  Mol Carcinog       Date:  2019-08-22       Impact factor: 4.784

8.  Chemistry of withaferin-A: chemo, regio, and stereoselective synthesis of novel spiro-pyrrolizidino-oxindole adducts of withaferin-A via one-pot three-component [3+2] azomethine ylide cycloaddition and their cytotoxicity evaluation.

Authors:  Yogesh P Bharitkar; Satish Kanhar; Neradibilli Suneel; Susanta Kumar Mondal; Abhijit Hazra; Nirup B Mondal
Journal:  Mol Divers       Date:  2015-03-08       Impact factor: 2.943

9.  Withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis.

Authors:  Green Kim; Tae-Hyoun Kim; Eun-Ha Hwang; Kyu-Tae Chang; Jung Joo Hong; Jong-Hwan Park
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

10.  Innate endophytic fungus, Aspergillus terreus as biotic elicitor of withanolide A in root cell suspension cultures of Withania somnifera.

Authors:  Ramesh Kumar Kushwaha; Sucheta Singh; Shiv Shanker Pandey; Alok Kalra; Chikkarasanahalli Shivegowda Vivek Babu
Journal:  Mol Biol Rep       Date:  2019-01-31       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.